ã¡ãã£ã¢èšäº
å¹ãã®ã?å¹ããªãã®ã? ã€ãã«ã¡ã¯ãã³ ã³ããæ²»çã«å¹æã¯âŠ
ããºãææ°ããŒã¯ 1,491
twitterã³ã¡ã³ã 516ä»¶äž 1ïœ100件
ã»ãã®æ²»çæ³ãæ²»çå¹æã®è§£èª¬ãããããâ
ããèšãåºæºãããã®ã
ç¥ãããã£ã
ç¥ãããã£ã
æåŸ
ããŠãã人éãããŸããããã€ãã«ã¡ã¯ãã³ã«æå¹æ§ãããã°è¯ãã£ããã ãã©ãçŸæç¹ã§æ°åã³ããã«å¯ŸããŠã®æå¹æ§ã¯ç€ºããŠããªããã§ããæå¹ã ã£ããã©ããªã«ãããâŠãŸããããã¯ããæçšãããšæããã©å¯äœçšãåºãªããŠè¯ãã£ãããããããããŸãšã貌ã£ãŠãããŸãã!
çŸæç¹ã§æ²»éšãã¯ãªã¢ããæ¿èªãããã³ããæ²»çè¬ã¯ïŒçš®é¡ã
ãšãããã人éçšã§ãåŠæ¹ç¡ãã§æçšããã®ã¯ãããæ¹ãããããããæã
ãŸããã§ãè²·ã£ãããšãã声ãèãã®ã§ã
âã€ãã«ã¡ã¯ãã³ã«é¢ããè«æã§ã¯ããŒã¿ãäžæ£ã«æäœãããçããææãããŠãããã®ã¯ããããææåã匷ããã«ã¿æ ªã«å¹ããèšåããè«æã¯ã»ãŒãªããªã©ãã¯ã£ããããããšãåãããªããâ
ãããŸã«èŠãããŸãããæ¬åœã«æãã§ããããåè¬ã§æ²»çè¬ãšããŠã¯èšåºçµæãåºæ¥ãŠããªããŠãããã«èæ©èœé害ãåºããšãããŸãããããçãèŠãªãã§æ¬²ãããã
ããã¯äœ¿çšããŠããæ²»çè¬ã®ããšãæžããŠãã£ããã§ããã£ã
èŠåºãããèªãŸããªãããšãå€ãã®ã«ãããããã¿ã€ãã«ãä»ããã®ã¯ç¡è²¬ä»»ã§ã¯ã
2021/8/23
âååœã®ä¿å¥åœå±ãWHOãã¡ãŒã«ãŒãªã©ã¯ããããŸã§ã®ãšããèšåºè©Šéšã§æå¹æ§ã¯æ確ã«ç€ºãããŠããªãâ
2021/8/23
âååœã®ä¿å¥åœå±ãWHOãã¡ãŒã«ãŒãªã©ã¯ããããŸã§ã®ãšããèšåºè©Šéšã§æå¹æ§ã¯æ確ã«ç€ºãããŠããªãâ
ã€ãã«ã¡ã¯ãã³ã®ååã°ãããèãããŠæ¥ãå°è±¡ã§ããã
ã³ããæ²»çè¬ã¯4ã€ãåœå ã§ã¯æ¿èªãããŠããããã§ãã
ã³ããæ²»çè¬ã¯4ã€ãåœå ã§ã¯æ¿èªãããŠããããã§ãã
çŸæç¹ã§ã¯ã€ãã«ã¡ã¯ãã³ãã³ããæ²»çè¬ãšããŠäœ¿ããªãã
ã¢ã¡ãªã«ã®FDAã¯ãçšéå€ãåç©çšã®ã€ãã«ã¡ã¯ãã³æçšã¯å±éºã ããå人ã§ã®æçšããããããåŒã³ãããŠãããšããèšäºããããŸããã©ãããã¯éµåã¿ã«ããªãæ¹ãè¯ãã£ãŠããšïŒ
ã¡ãŒã«ãŒã§ããããååãªç§åŠçæ ¹æ ã¯ãªãããšèšã£ãŠãã®ã«ïŒ
ã€ãã«ã¡ã¯ãã³ã«é¢ããèšäºã
ããå©çšãããšããŠããããã³ãšæ¿èªãããŠããã«ããŸãããã
ã
ããå©çšãããšããŠããããã³ãšæ¿èªãããŠããã«ããŸãããã
ã
ïŒç±³ã»FDA çšéå€ãåç©çšã®ã€ãã«ã¡ã¯ãã³æçšãæ¬æ°ã§ãããŠã
ðŽæ¬æ°ã§ðŽãããŠðŽ
ðŽæ¬æ°ã§ðŽãããŠðŽ
æç³»ã®äžè¬äººãšããŠã³ããã®è°è«ã«åå ã¯ããŸãããæ²»çãæè¬ãç 究ãšãã£ãå°éé åã«å£ã¯åºããªã䞻矩ã§ãããã®äžã§ã€ãã«ã¡ã¯ãã³ã«é¢ããŠã¯çŸå Žã®å»åž«ãç 究è
ã®éã§å®å
šã«èŠè§£ãåãããæ¿ããéé£åæŠãè¡ãããŠããããã§ããèªåãªãã«æŽçããŠã¿ãŸãã
æè¿ãã®æã®è©±ãç
©ããããªã£ãŠããã®ã¯ã¯ã¯ãã³2åæã¡çµãã£ãå¹æãããããŸãããïŒç¬ïŒ
åãã¯ãã³ã®äººãã¡ã¯ä»ãå¿ æ»ã«æŽ»åããŠããã§ãããã圌ãã®é«ãã¢ãããŒã·ã§ã³ãšè¡ååã¯çŽ æŽãããã®ã§ãæ©ãã¯ã¯ãã³æã£ãŠãã£ãšå€§åãªããšã«æŽ»èºããŠã»ããã
åãã¯ãã³ã®äººãã¡ã¯ä»ãå¿ æ»ã«æŽ»åããŠããã§ãããã圌ãã®é«ãã¢ãããŒã·ã§ã³ãšè¡ååã¯çŽ æŽãããã®ã§ãæ©ãã¯ã¯ãã³æã£ãŠãã£ãšå€§åãªããšã«æŽ»èºããŠã»ããã
èŠåºã4ã³ãããã
å¹æã®æãæ²»çè¬ãååšããŠããã®ã«ãä»ã«éžæè¢ãç¡ããšæã£ãŠã人ãçºçããŠããã®ã ããã
. â
ã€ãã«ã¡ã¯ãã³ã¯ã©ããªã£ãŠããã®ïŒã®ãŸãšãèšäº
å人çã«ã¯èšåºè©Šéš(RCT)ã§æå¹æ§ãšå®å šæ§ãããçšåºŠããããŸã§åŸ ã¡ãŸã
ã¯ã¯ãã³ãåæ§ã§ã
å®ç§ãæãã®ã¯ç¡ç
ã€ãã«ã¡ã¯ãã³ã¯ã©ããªã£ãŠããã®ïŒã®ãŸãšãèšäº
å人çã«ã¯èšåºè©Šéš(RCT)ã§æå¹æ§ãšå®å šæ§ãããçšåºŠããããŸã§åŸ ã¡ãŸã
ã¯ã¯ãã³ãåæ§ã§ã
å®ç§ãæãã®ã¯ç¡ç
ãããèŠãŠããç解ã§ããŸããã
ã³ããæ²»çè¬ãšãæäœã«ã¯ãã«ã®ããããªãŒãããããšã
èªåã¯ãããµã¡ãŸã³ïŒé å€ã¿ã€ãïŒãåŠæ¹ããŠããã£ãŠãŸãã
ã³ããæ²»çè¬ãšãæäœã«ã¯ãã«ã®ããããªãŒãããããšã
èªåã¯ãããµã¡ãŸã³ïŒé å€ã¿ã€ãïŒãåŠæ¹ããŠããã£ãŠãŸãã
ä»ã®ãšããé²ãã§äœ¿ããããªãã®ã§ã¯ãªãããšã
åéç 究æã®æ²»éšãé²ãŸãªãçç±ãå
ã
å°ãªãæ²»éšè
ãæŽã«æžã£ãäºã§ãã®çç±ãå»çéŒè¿«ïŒãå°ããã·ãªçå±ã§ãªããšèª¬åŸåç¡ãã§ããNHKãããååœã®æå¹æ§ãèªããæ²»éšçµæå ±åã¯ïŒ
ã€ãã«ã¡ã¯ãã³ã¯ã¢ããªã«ã§ã¯
å¹æããã
ãšããŠããåœããããŸã
å é²åœã§ã¯
æ°åã³ããã®æ²»çãšããŠãæå¹æ§ãå®å šæ§ã確ç«ããŠããªãããšã«çæããããšããè¬å€ã®äžã«äœçœ®ã¥ããŠããŸãã
倩ç¶çã®ã¯ã¯ãã³ã®çºèŠã¯
å¶ç¶ã®ç£ç©
ã¿ããã§ã
ä»åŸã®çµéã泚èŠ
å¹æããã
ãšããŠããåœããããŸã
å é²åœã§ã¯
æ°åã³ããã®æ²»çãšããŠãæå¹æ§ãå®å šæ§ã確ç«ããŠããªãããšã«çæããããšããè¬å€ã®äžã«äœçœ®ã¥ããŠããŸãã
倩ç¶çã®ã¯ã¯ãã³ã®çºèŠã¯
å¶ç¶ã®ç£ç©
ã¿ããã§ã
ä»åŸã®çµéã泚èŠ
èªç§°ä¿å®èšè«äºº
ãæ°åã³ããã®æ²»çè¬æ¢ãã«æ³šåããæ¹ãããã»ã©æ¯æçå埩ã«å¹æããã
è ç·ç
ãæåªå ã¯æ°åã³ãã察çã
æ¯æçor察ç
ã©ã¡ãã人åœåªå ãæçœã ã
ããšãã€ãã«ã¡ã¯ãã³ãã¯â¬ïžç»åãåèã«
ç¬æãšåèŠãããããäºå®ãã®ããã«èšãã®ã¯ãããŠããâŠ
ãæ°åã³ããã®æ²»çè¬æ¢ãã«æ³šåããæ¹ãããã»ã©æ¯æçå埩ã«å¹æããã
è ç·ç
ãæåªå ã¯æ°åã³ãã察çã
æ¯æçor察ç
ã©ã¡ãã人åœåªå ãæçœã ã
ããšãã€ãã«ã¡ã¯ãã³ãã¯â¬ïžç»åãåèã«
ç¬æãšåèŠãããããäºå®ãã®ããã«èšãã®ã¯ãããŠããâŠ
å
ã«åŠå®ãããã®æŸéããªã»ã»ã»èª°ãèŠãŠãã
æ§ã ãªã³ããŒããããŒã¿ã¯å®å šã«ç¡èŠãããŠãããå®å šæ§ã«ã€ããŠãå¯çè«ã«äœ¿ãããŠã®å¯äœçšãªã©ã¬ããŒããããŠãªãã
ç§ã¯äœ¿ãããŠããããŸãã
æ§ã ãªã³ããŒããããŒã¿ã¯å®å šã«ç¡èŠãããŠãããå®å šæ§ã«ã€ããŠãå¯çè«ã«äœ¿ãããŠã®å¯äœçšãªã©ã¬ããŒããããŠãªãã
ç§ã¯äœ¿ãããŠããããŸãã
ããããðå¯äœçšã£ãŠç¥ã£ãŠããïŒç¹ã«ã€ãã«ã¡ã¯ãã³âŠ
ã€ãã«ã¡ã¯ãã³ããå¹ãããšèšãåã ãã©ããå¹ãããšãã確ããããŒã¿ã¯ãªãããšèšã話ã
ã€ãã§ã«ãã¢ã¡ãªã«åœå
ã§ã¯FDAãã䜿çšãããªãšèŠåãåºãããšãã¯ãã€ãã«ã¡ã¯ãã³æçšããŠæ»äº¡ããŠãããäœäººãã
çã£åœãªã話ãããŠããã
è
ç·ç
ã¯ã·ã³ãã³DC - Front Line COVID-19 Critical Care Alliance ïŒFLCCCïŒã¯ãå šã€ã³ãå»ç§å€§åŠïŒAIIMSïŒããã®æè¿æŽæ°ãããã¬ã€ãã³ã¹ã称è³ããã€ãã«ã¡ã¯ãã³ãæ²»çã®ã¬ã€ãã©ã€ã³ã«å«ããŸããã
ã¯ã·ã³ãã³DC - Front Line COVID-19 Critical Care Alliance ïŒFLCCCïŒã¯ãå šã€ã³ãå»ç§å€§åŠïŒAIIMSïŒããã®æè¿æŽæ°ãããã¬ã€ãã³ã¹ã称è³ããã€ãã«ã¡ã¯ãã³ãæ²»çã®ã¬ã€ãã©ã€ã³ã«å«ããŸããã
å
é±ãã€ãã«ã¡ã¯ãã³ã¯ã©ããâŠãšãã£ãã¹ã¿ã³ã¹ã®çªçµãæã£ãNHKã
åªã³ãé£äžã«ãžã€ãã£ãçªçµãªã©ãŽããã£ãŠæµããããããé¢ã®ç®ã ð€£
åªã³ãé£äžã«ãžã€ãã£ãçªçµãªã©ãŽããã£ãŠæµããããããé¢ã®ç®ã ð€£
çŸåšãååŽçãæ¿èªããŠããæ²»çè¬ã¯ãç¹æ»Žå€ã®ã¬ã ãã·ãã«ãšæäœã«ã¯ãã«ãªã©4çš®ã
çµå£é å€ã®ã€ãã«ã¡ã¯ãã³ãã¢ãã¬ã³ã¯æ¿èªãããŠãªãã
ç±³åœã®åæ²»çè¬éåã¯å端ãªãâŒïž
ä»åŸå¹Žæ«ãŸã§ã«äŸçµŠäºå®ã®ã·ãªãã®è£œè¬ã®å€ç°ã«ãå¹ãçµå£é å€ã«å§åãããããªãäºãé¡ãã
çµå£é å€ã®ã€ãã«ã¡ã¯ãã³ãã¢ãã¬ã³ã¯æ¿èªãããŠãªãã
ç±³åœã®åæ²»çè¬éåã¯å端ãªãâŒïž
ä»åŸå¹Žæ«ãŸã§ã«äŸçµŠäºå®ã®ã·ãªãã®è£œè¬ã®å€ç°ã«ãå¹ãçµå£é å€ã«å§åãããããªãäºãé¡ãã
äœé£æç®ã ãâŠâŠ
ããã§ããããã
ã³ããã®æ²»çè¬ã¯ãçå®ã«å¢ãç¶ããŠããããã©ãæ²»éšãããã«ã¯æ¬æ¥ã¯æ°å¹Žåäœã®æéããããã
åã¯ã¯ãã³ãããããã«ã¯å¯èœãªéãã®äººãšã®æ¥è§Šæžãããããªããã©ããã¹ãç³»ã®äººã«ã¯ãŠã€ã«ã¹ããªããŠãã人ãå€ãæ°ãããã
åã¯ã¯ãã³ãããããã«ã¯å¯èœãªéãã®äººãšã®æ¥è§Šæžãããããªããã©ããã¹ãç³»ã®äººã«ã¯ãŠã€ã«ã¹ããªããŠãã人ãå€ãæ°ãããã
å°ãåã«ãã£ãèšäºè²Œã£ãšããŸã
(ã£ËËË)ã£ïŸïŸïŸïœ¯
ç§ã«ã¯ãã®æè¬ãããã®ãæªãã®ãåãããªããã© ããããã³ãããååšããªããšãèšã£ãŠã人ãæçšããã£ãŠããšã¯å¯çè«ãç¥ç¬ãšæŠã£ãŠããšããâŠð€£
(ã£ËËË)ã£ïŸïŸïŸïœ¯
ç§ã«ã¯ãã®æè¬ãããã®ãæªãã®ãåãããªããã© ããããã³ãããååšããªããšãèšã£ãŠã人ãæçšããã£ãŠããšã¯å¯çè«ãç¥ç¬ãšæŠã£ãŠããšããâŠð€£
ãªãã»ã©å
çæ¹ã®ãã£ãããããšãããªãã¡ééãã§ã¯ãªããã çµå±ãæŸçœ®ãããã«ãããŒã«ãããããäžããããŠããªãæ£è
ãèŠãããŠããããšã«è·æ
ããŠããã®ã§ã¯ãªããã
èå³æ·±ãã®ãæµããŠããã®ã§
æ»èªæžã®è¯å®çãªè«æãä»ã®è¬ããå°ãªããããªããšããªãããã¬ã ãã·ãã«ãæäœã«ã¯ãã«çéžæè¢ã¯ããã®ã«ãªããããªã®ãçåã
åäººèŒžå ¥ã§å¯äœçšã ããŠéçãšãæãããæ°ãã€ããŠãªã
æ»èªæžã®è¯å®çãªè«æãä»ã®è¬ããå°ãªããããªããšããªãããã¬ã ãã·ãã«ãæäœã«ã¯ãã«çéžæè¢ã¯ããã®ã«ãªããããªã®ãçåã
åäººèŒžå ¥ã§å¯äœçšã ããŠéçãšãæãããæ°ãã€ããŠãªã
NHKã§ãå ±ããŠãŸãã
ã€ãã«ã¡ã¯ãã³ã ã£ãŠããã£ããæ ¹æ ããããããããªãã®ã«äœæ
ãé Œããã ããªãã
ã¯ã¯ãã³ã¯ä¿¡çšåºæ¥ãªããŠãã€ãã«ã¡ã¯ãã³ã¯ä¿¡çšã§ããã®ã¯äœæ ïŒïŒïŒ
ã¯ã¯ãã³ã¯ä¿¡çšåºæ¥ãªããŠãã€ãã«ã¡ã¯ãã³ã¯ä¿¡çšã§ããã®ã¯äœæ ïŒïŒïŒ
ã€ãã«ã¡ã¯ãã³ã¯ çŸåšã®ãšããå¹æãæåŸ
ã§ããªãããã å人茞å
¥ãšãå®æãªäœ¿çšã¯ å¯äœçšã®ç¹ã§ ããã£ãŠåœãšããã
ãã以å€ã®æ²»çè¬ã玹ä»ãããŠã㊠ããããããèšäºã§ãâ 貌ã£ãšããŸã
ãã以å€ã®æ²»çè¬ã玹ä»ãããŠã㊠ããããããèšäºã§ãâ 貌ã£ãšããŸã
å»è
ã§ãã¢ããããã®ã«ãçŽ äººãæãåºããã®ãããªãããã¯ã¹ãªã®å¯äœçšããã¡ãŠã¯ãããªããïŒ
æ²»éšïŒäººäœå®éšã£ãŠãã人ããããã©ããã®æ²»çè¬ãæå¹ãããããªããšããæ£è
ããã«å¯ŸããŠæ²»çãè¡ãããã«ããçšåºŠã®å®å
šæ§ãæå¹æ§ãªã©ã確èªããäžã§ãããªã£ãŠãããã ããããããã®ãã©ãããšæãã®ããã
ãã®ç¿»èš³ããŸããªããå¥èªæ³ã埮åŠã«ããããŠãåæã® "y'all" ã®é°å²æ°ãåºããŠãã
ð
ã³ããã«éããäžå®ãªç¶æ ã«ãªããšèª€ã£ãæ å ±ãäžç¢ºããªæ å ±ã«æãããããããªããå ¬çãªæ©é¢ããåºãããæ å ±ãªã©ãããšã«ã¬ãã«ã®é«ãæ ¹æ ã«è£æã¡ãããŠããããã£ããèŠãå¿ èŠããã
ã³ããã«éããäžå®ãªç¶æ ã«ãªããšèª€ã£ãæ å ±ãäžç¢ºããªæ å ±ã«æãããããããªããå ¬çãªæ©é¢ããåºãããæ å ±ãªã©ãããšã«ã¬ãã«ã®é«ãæ ¹æ ã«è£æã¡ãããŠããããã£ããèŠãå¿ èŠããã
ãªããªãé£ãããããã£ãŠæŸçœ®ãããã䜿ããããªããã
> åœåã®èšç»ã§ã¯ããšã3ææ«ãŸã§ã«240人ã察象ã«ããèšåºè©ŠéšãçµãããšããŠããŸããããåéç 究æã«ãããŸããšãçžæ¬¡ãæææ¡å€§ã§åç
é¢ã§ã¯çç¶ãéãæ£è
ã®æ²»çãåªå
ããããããªãç¶æ³ãç¶ããããšã6æã®æç¹ã§åå ããæ£è
ã¯åæ°çšåºŠã«ãšã©ãŸã£ãŠãããšããããšã§ã
ã¯ã¯ãã³ã¯æ¯ã ãªãã ãšãã人ã¯ãªãã€ãã«ã¡ã¯ãã³ãæªãèšããã®ã ããïŒããããåã¯ã¯ãã³å©æš©ãªããŠããããããã ãããïŒ
èŠæžãšããŠãã€ãŒã
ãšããããã³ã¬âŠã§åé倧åŠã§å¹ãããããïŒãšèšãããŠãŸãã⊠ïŒç¶ã
NHKã¯ã€ãã«ã¡ã¯ãã³ãåŠå®ãæ¢ããã¹ãçç±ã°ããçŸ
åããŠãããã§ããã©ïŒäœããã埡äžããã®ç¹åœããã£ãã®ãïŒ(^^;
ã¯ã¯ãã³æ¥çš®ã¯å¿
é ããã®äžã§äžå¯ãé¿ããè¡åæå¶ãææããå Žåã¯æ©æã®æäœã«ã¯ãã«çæ³ãªã©ãã¯ã¯ãã³ãšã®åããæã§ãªããšå¯Ÿæã§ããªãã
åãããããã£ãã
å¹æã®å¯èœæ§ãããã°ãã®ã¿ã€ãã«ã§ãããšæããã
ããã§ããåŸ ã£ãŠã€ãã«ã¡ã¯ãã³ããããã劥åœãªé¡åã§ãããæé¢çã«ã
ããã§ããåŸ ã£ãŠã€ãã«ã¡ã¯ãã³ããããã劥åœãªé¡åã§ãããæé¢çã«ã
åããããããè¯ããŸãšãŸã£ãŠãã
åŠå®çãªæèŠãããéããŠã¿ãŸããã
éã«æªãããæãããã
éä¿¡ã¯è¯ããªãããã©ãå¯äœçšãããŸããªããå¹æãæåŸ ã§ãããªããæ©ãæ¿èªããŠæ¬²ãããåœãæããã®ãªãã
éã«æªãããæãããã
éä¿¡ã¯è¯ããªãããã©ãå¯äœçšãããŸããªããå¹æãæåŸ ã§ãããªããæ©ãæ¿èªããŠæ¬²ãããåœãæããã®ãªãã
çŸæç¹ã§ã®æåã¯ãâ ã¯ã¯ãã³ã«ããäºé²â¡è»œçæã®æäœã«ã¯ãã«æäžâ¢â¡ã®å¯Ÿå¿ãå»åž«ãåºãåºæ¥ãããã«èªå®
çé€ããèšæå»çæœèšã®èšçœ®ãŠããšãªã®ããªð€
ã€ãã«ã¡ã¯ãã³ã«ã€ããŠç±³FDAããããªãã¯éŠ¬ãããªããçã§ããªããæ¬æ°ã§çãããããŠãã ããã
ã€ãã«ã¡ã¯ãã³ã«ã€ããŠã¯NHKã®èšäºãåãããããã£ãã®ã§è²Œã£ãŠãããŸã
ããŸããã€ãã«ã¡ã¯ãã³ã補é ããã¢ã¡ãªã«ã®è£œè¬å€§æãã¡ã«ã¯ãã2æãæ°åã³ãããŠã€ã«ã¹ãžã®æ²»çå¹æã«ã€ããŠååãªç§åŠçæ ¹æ ã¯ãªãããšãã声æãåºããŠããŸããã
ã©ã®æ
å ±ãä¿¡é Œãã¹ãããšããææšã®ã²ãšã€ã«ãããšããã³ã¹ã¬ãã«ããããããšããã³ã¹ã¬ãã«ãæé«ã ãããšãã£ãŠ100%æ£ãããšã¯éããªãããäœããã®ã«è³ããŠè£åããããããã¯ãã·ã ãšæãã
ã€ãã«ã¡ã¯ãã³ãæå®å€ã§æäŸããå人茞å
¥ãµãŒãã¹ã
12mg X 100é ã6280åïŒ
ãcure19 ã€ãã«ã¡ã¯ãã³ãã§ã°ã°ã£ãŠãã ããã
12mg X 100é ã6280åïŒ
ãcure19 ã€ãã«ã¡ã¯ãã³ãã§ã°ã°ã£ãŠãã ããã
ã¡ãããšèª¿ã¹ãå ±éã§ãç¥ãã¹ãå
容(åæã«æçšããŠå¥åº·è¢«å®³ãåºãŠãã件ã)ããã¡ããšæã£ãŠããããä¿¡è
ã¯èªãŸãªããã ãããªã
å»åŠçã«æ ¹æ ç¡ããŠããæ¬äººãå¹ããšãæ²»ã£ãã£ãŠèšããªããªãã§ãããŒãããããªåŒ±æ¯ããã®ã€ãã«ã¡ã¯ãã³ã§æ»ãã 奎ãšããããŒãã ãïŒã«ã«ã§ãããŒãããã£ããšçµããããð¢
ããã¯èãããªããããã©ãã©ãããæ©åºã§å¹ãã®ïŒïŒïŒ
å¹ãã®ã?ã€ãã«ã¡ã¯ãã³
ã€ãã«ã¡ã¯ãã³ã¯ãã»ãšãã©äœ¿ãããŠããªãããã§ãã
軜çåæã«æäœã«ã¯ãã«ã䜿ããå§ããŸãããããŸã éãéãããŠããŸãã
å¹æããããã§ãã
ã©ã®ç é¢ã§ã©ããªæ£è ã«äœ¿ãããŠããã®ãã¯æããŠãããããã§ãã
ã€ãã«ã¡ã¯ãã³ã¯ãã»ãšãã©äœ¿ãããŠããªãããã§ãã
軜çåæã«æäœã«ã¯ãã«ã䜿ããå§ããŸãããããŸã éãéãããŠããŸãã
å¹æããããã§ãã
ã©ã®ç é¢ã§ã©ããªæ£è ã«äœ¿ãããŠããã®ãã¯æããŠãããããã§ãã
ãé«éœ¢è
ãåŠåš äžã®å¥³æ§ãžã®æäžã®å®å
šæ§ã¯ç¢ºç«ããŠããªãããä»åŸãæå¹æ§ã瀺ãããããšããããããããªãããçŸæ®µéã§ã¯ç€ºãããŠãããå人ã®å€æã§æçšããã®ã¯ãããã»ããããã
ãããŸããŸãªç 究çµæãå ±åãããŠããŸãããæå¹æ§ã¯åå蚌æãããŠããããç 究ãç¶ããŠããŸãããæ¥æ¬åœå
ã§ã¯æ°åã³ããã®æ²»çè¬ãšããŠã¯æ¿èªãããŠãããã
ãWHOã¯3æãïŒç¥ïŒæ°åã³ããæ£è
ã§æ»äº¡çã®äœäžãå埩ãæ©ããç§åŠçæ ¹æ ããããã©ããã¯ã極ããŠäžç¢ºå®ã ããšææããŠããŠãã€ãã«ã¡ã¯ãã³ã®æäžã¯èšåºè©Šéšã«éãããæšå¥šããŠããŸãã
ãå¯çè«ãåå ã§å€±æãªã©ãåŒãèµ·ããããææçã®ç¹å¹è¬ãã€ãã«ã¡ã¯ãã³ããã现èã䜿ã£ãå®éšã§å»å¹Žãæ°åã³ãããŠã€ã«ã¹ã®å¢æ®ãæããå¹æããããšããçµæãåºããã
ã€ãã«ã¡ã¯ãã³ã®æå¹æ§ã¯èšŒæãããŠããããæ°åã³ããã®æ²»çè¬ãšããŠã¯èŠãŠèªããŠãããŠããŸããã
ãã£ã±ããªããããšããã³ã¹ã¬ãã«ããã£ã¡ãäœããããæ®æ®µããããšããã³ã¹ããŒããšããã³ã¹ããŒãã£ãŠMRã«æ£ã
æå¥èšã£ãŠã人éãã©ã®å£ã§èšãã®ãããšèšã話ã§ãã
ã€ãã«ã¡ã¯ãã³ã«ã€ããŠNHKã«ãŠ
NHKã§ã€ãã«ã¡ã¯ãã³ã®å¹æã«é¢ããæŸéããã£ãããããæ¥æ¬ã§ã¯ãã³ããæ²»çè¬ãšããŠæ¿èªããŠããªãããããã èšåºè©Šéšã§æå¹æ§ã調æ»ãæµ·å€ã®å¹æãããšããæç®ã®ä¿¡é Œæ§ã¯äœãããšããã³ã¹ã¬ãã«ïŒæ
å ±ã©ã³ã¯ïŒã«ããä¿¡é Œæ§ã§å€æã
ããããšãããããŸãããã ããã®èšäºã¯å¹æããã£ããšå
çãæããããŠããåœã§éçè
ãæžããããšã«åœ¹ç«ã£ãäºã蚌æããŠãããŸããã
æ®å¿µãªããã€ãã«ã¡ã¯ãã³ãã³ããæ²»çã«æå¹ã§ããããšã¯èšŒæãããŠããªãã®ãçŸç¶ã ãšæããŸãã
æ®å¿µãªããã€ãã«ã¡ã¯ãã³ãã³ããæ²»çã«æå¹ã§ããããšã¯èšŒæãããŠããªãã®ãçŸç¶ã ãšæããŸãã
ãããããããªã
ã€ãã«ã¡ã¯ãã³ã®èšäºã§ãã
ã2021幎8æ23æ¥ã
ããããµã¡ã¿ãŸã³ã
ãå»å¹Ž7æã«åçåŽåçãæ²»çè¬ãšããŠæšå¥šããããççãã¢ã¬ã«ã®ãŒãæããäœçšã®ããã¹ããã€ãå€ã
ãã¬ã ãã·ãã«ã
ãããšããšã¯ãšãã©åºè¡ç±ã®æ²»çè¬ããå»å¹Ž5æã«ç¹äŸæ¿èªãããã®ãæãŠã€ã«ã¹è¬ããç¹æ»Žã§æäžã
ããããµã¡ã¿ãŸã³ã
ãå»å¹Ž7æã«åçåŽåçãæ²»çè¬ãšããŠæšå¥šããããççãã¢ã¬ã«ã®ãŒãæããäœçšã®ããã¹ããã€ãå€ã
ãã¬ã ãã·ãã«ã
ãããšããšã¯ãšãã©åºè¡ç±ã®æ²»çè¬ããå»å¹Ž5æã«ç¹äŸæ¿èªãããã®ãæãŠã€ã«ã¹è¬ããç¹æ»Žã§æäžã
ãã®ãžããé¢çœã
ããããã©ããªãããâŠïŒ
銬ãçã®éã飲ããã€ãããã®ãïœïœïŒåã¯ã¯ãã³ã泚å°ãããžãžã€ãšäžç·ã ãªãå¯äœçšã§é£ãã§ããããããïŒãã®äžã«ïŒ
ãã€ãã«ã¡ã¯ãã³ãã«ã€ããŠãé販ãµã€ããªã©ã§ã¯ãæ°åã³ãããŠã€ã«ã¹ãžã®æ²»çå¹æãæåŸ
ãããŠããããªã©ãšããŠè²©å£²ãããå人çã«è³Œå
¥ããããšãããšãã§ããã
ãããåè¬ããã©ãããã®ãšãã«çœ®ããŠã»ãããã ãã©ã
èå¿ãªæ å ±ããªãã
èå¿ãªæ å ±ããªãã
ä»ã®ãšããã䜿ãããããªããšããã®ãæ£ãããã§ããã
ãªãã»ã©ïœ
ã³ããã«ãªã£ãŠã©ã³ãã åæ¯èŒè©Šéšã«åå ããŠ
åœè¬ãåŠæ¹ãããŠéçåãããæããª
ã³ããã«ãªã£ãŠã©ã³ãã åæ¯èŒè©Šéšã«åå ããŠ
åœè¬ãåŠæ¹ãããŠéçåãããæããª
ã¿ã€ãã«ã¯ãå¹ãã®ã?å¹ããªãã®ã?ãã§ãªãåé ã«ããããããŸã§ã®ãšããèšåºè©Šéšã§æå¹æ§ã¯æ確ã«ç€ºãããŠããªãããçãããã°ããã®ã«ãä»ã®ãŸãŸã ãšäž¡è«ãæ®æããŠããããã«èŠããïŒ
ãããããããããããªð¥º
WHOããã€ãïœãäœã£ãŠã補è¬äŒç€Ÿèªèº«ããå¹æãªããã£ãŠèšã£ãŠãã
WHOããã€ãïœãäœã£ãŠã補è¬äŒç€Ÿèªèº«ããå¹æãªããã£ãŠèšã£ãŠãã
ååœã®å°é家ãè«æãæ€èšŒããŠç§åŠçãªæ ¹æ ãããã調ã¹ãŠããåœéçãªãŠã§ããµã€ããã³ã¯ã©ã³ãã¯å
ææ«ãã€ãã«ã¡ã¯ãã³ã®æå¹æ§ã«ã€ããŠãæ²»çãäºé²ã®ããã«äœ¿çšããããšãæ¯æããç§åŠçãªæ ¹æ ã¯çŸæç¹ã§ã¯èŠã€ãããªãã£ãããšããçµæã瀺ãããšã®ããš
ããããªãã§ã¯ã¯ãã³ã¯å€§éã«æåãããã®ã
æå³äžæã§ãã
æå³äžæã§ãã
ïŒNHKãŸã§åç©ãã¿ã§åŒ·è«ããšã¯ïŒç±³ã»FDA çšéå€ãåç©çšã®ã€ãã«ã¡ã¯ãã³æçšãæ¬æ°ã§ãããŠã
æ®éæ²»éšã«ã¯è«å€§ãªãéãããã
æ²»éšè ãžã®è¬ç€Œãªã©æŽèœã«ãªããªãããã
倧åŠã®ç 究費ã§è³ããã¯ãããªãã倧ã¹ãã³ãµãŒã®ååãªãããŠæãåŸãªã
ãã ãèªå® çé€ãå€ãä»ãªããæ²»éšã«å¿é¡ãããææè ãå± ãã¯ã
èªåãã³ããã«çœ¹ã£ããæ²»éšåå ããã
ã§ð
æ²»éšè ãžã®è¬ç€Œãªã©æŽèœã«ãªããªãããã
倧åŠã®ç 究費ã§è³ããã¯ãããªãã倧ã¹ãã³ãµãŒã®ååãªãããŠæãåŸãªã
ãã ãèªå® çé€ãå€ãä»ãªããæ²»éšã«å¿é¡ãããææè ãå± ãã¯ã
èªåãã³ããã«çœ¹ã£ããæ²»éšåå ããã
ã§ð
NHKã£ãŠåæšãé¿ããã¯ããããªãã£ãã®ããªãã§äžè¬åãããªããŠåæšåã§èšèŒãããŠããè¬ãããã®ð€
ãååœã®ä¿å¥åœå±ãWHOïŒäžçä¿å¥æ©é¢ãã¡ãŒã«ãŒãªã©ã¯ããããŸã§ã®ãšããèšåºè©Šéšã§æå¹æ§ã¯æ確ã«ç€ºãããŠããªããšããŠããŸãã
ã¡ãŒã«ãŒèªèº«ãããèšã£ãŠããã®ã«ã
ã¡ãŒã«ãŒèªèº«ãããèšã£ãŠããã®ã«ã
â
ãã£ããèªãã§ã¿ãã
ç»åã¯äžèšèšäºããåŒçšããã®ç»åã ãã§ãããããªäººã«èŠãŠæ¬²ããã
æ
å ±æŽçã®ããã
ð ã«å¯Ÿããåçµç¹ã®èŠè§£
ð¹WHOïŒç§åŠçæ ¹æ ãäžç¢ºå®
ðºðžåœç«è¡çç 究æNIHïŒæå¹ãçµè«åºããªã
ðºðžè£œè¬äŒç€Ÿã¡ã«ã¯MerckïŒå¹æã®ç§åŠçæ ¹æ ãªã
ðºðžé£åå»è¬åå±FDAïŒåç©çšã䜿ããªãããèŠå
ð¯ðµååŽçïŒæå¹æ§ãå®å šæ§ã«çæ
â»8æ23æ¥NHKãã¥ãŒã¹WEB ãã
ð¹WHOïŒç§åŠçæ ¹æ ãäžç¢ºå®
ðºðžåœç«è¡çç 究æNIHïŒæå¹ãçµè«åºããªã
ðºðžè£œè¬äŒç€Ÿã¡ã«ã¯MerckïŒå¹æã®ç§åŠçæ ¹æ ãªã
ðºðžé£åå»è¬åå±FDAïŒåç©çšã䜿ããªãããèŠå
ð¯ðµååŽçïŒæå¹æ§ãå®å šæ§ã«çæ
â»8æ23æ¥NHKãã¥ãŒã¹WEB ãã
ãã€ãã«ã¡ã¯ã㳠泚æããšæ€çŽ¢ããŠã¿ããšããªãã€ãããã¯ã¯ãã³ã«å察ããŠãŠãªãã³ããæ²»çè¬ãšããŠæªæ¿èªã®ã€ãã«ã¡ã¯ãã³ã¯é£²ãããšããã®ã ãããã»ããšæããããªããéã ãã
ã
ã
æ²»éšã®ä¿¡é ŒåºŠçã¯ãã¡ããåãããããã§ãã
å㞠次ãž